Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 20/20 | 0.81 |
| ▸ | AURKA | O14965 | 15/20 | 0.81 |
| ▸ | AKT1 | P31749 | 2/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.81 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665990 | 0.89 | RPS6KB1 (1.00) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL663752 | 0.89 | RPS6KB1 (1.00) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL667609 | 0.88 | RPS6KB1 (1.00) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL665240 | 0.88 | RPS6KB1 (1.00) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL16162103 | 0.87 | RPS6KB1 (0.67) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL10255470 | 0.84 | RPS6KB1 (1.00) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL16459765 | 0.84 | RPS6KB1 (0.79) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL665088 | 0.83 | RPS6KB1 (1.00) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL15762468 | 0.83 | AKT1 (0.77) | RPS6KB1AURKAAKT1AURKBINCENP | |
| SCHEMBL20178074 | 0.83 | AKT1 (0.77) | RPS6KB1AURKAAKT1AURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396307-B1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2014-10-15 | — | — | EP | claimed |
| US-8637532-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | claimed |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | US | claimed |
| CN-102317269-A | Novel amino aza heterocyclic carboxamides | MERCK PATENT GMBH | 2012-01-11 | — | — | CN | claimed |
| EP-2396307-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2011-12-21 | — | — | EP | claimed |
| WO-2010093419-A1 | NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2010-08-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | AZI2, MKI67, MYC | RPS6KB1 500/4885AURKA 600/4885AKT1 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.